Form 8-K - Current report:
SEC Accession No. 0001558370-25-007491
Filing Date
2025-05-13
Accepted
2025-05-13 07:26:42
Documents
15
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20250513x8k.htm   iXBRL 8-K 36249
2 EX-99.1 ymab-20250513xex99d1.htm EX-99.1 335136
3 GRAPHIC ymab-20250513xex99d1001.jpg GRAPHIC 5043
  Complete submission text file 0001558370-25-007491.txt   522346

Data Files

Seq Description Document Type Size
4 EX-101.SCH ymab-20250513.xsd EX-101.SCH 3412
5 EX-101.LAB ymab-20250513_lab.xml EX-101.LAB 15927
6 EX-101.PRE ymab-20250513_pre.xml EX-101.PRE 10319
17 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20250513x8k_htm.xml XML 4849
Mailing Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540 646-885-8505
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 25937138
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)